Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
alnylam pharmaceuticals
boston
boston blog main
boston top stories
fda
hereditary transthyretin amyloidosis
3
×
life sciences
national blog main
national top stories
patisiran
3
×
akcea therapeutics
clinical trials
inotersen
new york blog main
new york top stories
onpattro
pfizer
rna interference
san diego blog main
san diego top stories
tafamidis
alexion pharmaceuticals
andrew fire
biotech
boehringer ingelheim
craig mello
deals
dicerna pharamceuticals
drugs
european medicines agency
harvard pilgrim health care
hepatitis b
hepatitis b virus
institute for clinical and economic review
john maraganore
nobel prize
roche
san francisco blog main
san francisco top stories
vyndaqel
What
drug
3
×
alnylam
fda
gene
medicine
pharmaceuticals
protein
rnai
afternoon
alnylam’s
approved
approves
caught
causing
cells
dicerna
disease
ema
employ
europe
eye
follows
gets
harmful
hepatitis
history
hits
intended
interference
landmark
make
making
medicines
method
mute
ok
onpattro
patisiran
pay
pharma
Language
unset
Current search:
patisiran
×
drug
×
" hereditary transthyretin amyloidosis "
×
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug